Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mirum Awaits EMA Verdict On ‘Reprioritized’ Livmarli Filing

Executive Summary

Mirum could soon find out if its decision to reprioritize its EU filings for its rare liver disease drug has paid off.

You may also be interested in...



EU Moment of Truth For Abaloparatide & Advanced Therapy Tab-Cel

Radius’s abaloparatide, which was previously rejected by the European Medicine Agency, is among the latest products that are this week being considered for EU-wide marketing approval by the agency.

EU Moment of Truth For Abaloparatide & Advanced Therapy Tab-Cel

Radius’s abaloparatide, which was previously rejected by the European Medicine Agency, is among the latest products that are this week being considered for EU-wide marketing approval by the agency.

Qdenga: Crunch Time For First Product In Parallel Review Route For EU And Non-EU Markets

Takeda could soon learn whether the European Medicines Agency will recommend in favor of approving its dengue vaccine, which was reviewed under a new evaluation route that simultaneously targets EU and non-EU countries.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS147136

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel